Genmab — September 2017

[JKY_VH]

God morgen, håber du nyder klimaet i Malaga bibob

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

Tak JKY. Varmen er god for en " halvgammel " krop.

[Her_for_at_lære]

Hvad er det vi forventer at høre fra ESMO i denne måned fra Genmap? God dag til alle

[bibob]

Bla. gode data fra Tisotumab studier.

[bibob]

Håber at 1440 holder i dag.

[Her_for_at_lære]

Tak Bibob! Men var det ikke det, som GENMAP annoncerede tidligere i August?

[bikube]

Du må være Her for at lære, at det hedder Genmab.

[bibob]

Tommel op bikube.

[Her_for_at_lære]

Beklager, de herrer

[E_L]

Is CAR-T always targeting CD19? I am thinking again about the MacroGenics / Janssen termination of the CD19-targeting Duvortuxizumab which Solsen posted last week. Can I see this as a blow to CAR-T also?

[Bulder]

Det er ofte (vel især) BCMA, som er target. F.eks. Bluebird's https://endpts.com/bluebird-has-a-promising-new-update-on-its-bcma-car-t-for-multiple-myeloma-but-is-it-still-the-leader/

[Bulder]

Også Kite har noget kørende mod BCMA http://ir.kitepharma.com/releasedetail.cfm?releaseid=1036443

[E_L]

ok, thank you Bulder

[Solsen]

https://www.cancer.gov/about-cancer/treatment/research/car-t-cells In many CAR-T programs its CD19 which is the target.

[Sukkeralf]

Also Legend Biotech has a BCMA CAR-T and also a few bispecific antibodies targeting BCMA

[Sukkeralf]

Nothing wrong with CD19 as a target I guess

[Solsen]

Genmab think so

[Solsen]

.....siger NL

[Solsen]

De har dog købt nogle licenser fra BMS i 2015 til netop cd19 ?